NEW YORK--(BUSINESS WIRE)--Medidata Solutions today announced that AstraZeneca (NYSE: AZN) has chosen to standardize on Medidata Rave® electronic clinical data capture (EDC), management and reporting solution as part of a plan to fully migrate to paperless clinical trials. Medidata Rave will help AstraZeneca replace its in-house EDC system and other EDC products for studies across all therapeutic categories in its diverse portfolio. AstraZeneca plans to implement Medidata Rave in many of its studies worldwide.
